DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Journey Medical Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$5.17+0.21 (+4.13%)

Close on Oct 19, 2026

Market cap: $142.14M
P/E (TTM): –
Dividend yield: –

Journey Medical Corp cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Depreciation & Amortization	–	–	–	–	0	0.01
Stock-Based Compensation	6.29	6.10	2.61	4.43	2.47	0.15
Deferred Income Taxes	–	–	–	–	1.57	-0.34
Change in Accounts Receivable	-19	4.48	13	-5.38	0.77	-5.02
Change in Inventory	4.81	-4.23	3.95	1.74	-8.46	-0.55
Change in Accounts Payable	-7.20	-2.10	-18	14	20	-0.20
Operating Cash Flow	-12	-9.13	5.24	-14	-2.18	5.13
Capital Expenditures	–	-15	-5.00	-20	–	–
Investing Cash Flow	–	-15	-5.00	-20	-10	-1.20
Stock Issued	16	7.88	4.49	–	33	–
Financing Cash Flow	16	17	-4.80	16	53	-0.49
Net Change in Cash	3.79	-7.13	-4.56	-17	41	3.45
Free Cash Flow	–	-24	0.24	-34	–	–
Income Taxes Paid	0.05	0.13	0.18	0.17	0.16	0.11
Interest Paid	3.24	2.01	1.13	0.99	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 65.5%
Operating margin: -4.4%
Net margin: -9.0%
Return on equity, FY2025: -44.0%

Financial strength

Current ratio: 1.59
Debt to equity: 0.79
Debt to assets: 25.9%
Cash to current liabilities: 56.0%

Valuation

P/E ratio: –
Price to sales: 2.08
Price to book: 4.43
Dividend yield: –